Prestige Consumer Healthcare Inc (PBH) Fair Value & Analysis
Healthcare · US · Market cap $2.2B
Prestige Consumer Healthcare Inc
PBH · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price +1.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $43.57 – $77.56 · fair‑value band $42.68 – $110.47 · the $46.05 price screens below the $79.12 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Prestige Consumer Healthcare Inc (PBH) currently trades at $46.05, while our model-based Fair Value estimate is $79.12 — implying the stock looks roughly 71.8% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Prestige Consumer Healthcare Inc generated revenue of $1.1B at a net margin of 17.5%. Revenue declined 5.0% year over year. It earns a return on equity of 10.2%. Net debt stands at $982M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dram…
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Prestige Consumer Healthcare Inc reported revenue of $1.1B in FY2026 versus $1.1B in FY2022, a compound +0.0%/yr. Reported net income was $190M in FY2026, compounding −1.9%/yr from FY2022.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prestige Consumer Healthcare Inc (PBH) undervalued?
What is the fair value of PBH?
What is the quality score of PBH?
What is the revenue of Prestige Consumer Healthcare Inc (PBH)?
What is the net profit margin of PBH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.